Trials / Completed
CompletedNCT04649112
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Precision BioSciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | PBCAR19B | Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused |
Timeline
- Start date
- 2021-06-16
- Primary completion
- 2022-12-22
- Completion
- 2023-09-30
- First posted
- 2020-12-02
- Last updated
- 2024-07-26
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04649112. Inclusion in this directory is not an endorsement.